Central Nervous System Diseases  >>  ponezumab (PF-04360365)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ponezumab (PF-04360365) / Pfizer
NCT00945672 / 2009-011172-30: A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Completed
2
36
Europe
PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg, placebo
Pfizer
Alzheimer's Disease
06/11
06/11
NCT01821118 / 2013-001557-27: Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

Completed
2
36
US, Canada, Europe
Ponezumab, placebo
Pfizer
Cerebral Amyloid Angiopathy
09/15
09/15

Download Options